| Početna strana | Uredništvo | Časopis  | Uputstvo autorima  | Kodeks u  kliničkom i eksperimentalnom radu | Kontakt  |  
| Home page | Editorial  board | About the Journal | Instructions for Authors | Peer Review Policy | Clinical and Experimental Work Code | Contact  |


Acta Medica Medianae
Vol. 54, No 1, March, 2015

UDC 61
ISSN 0365-4478(Printed version)
ISSN 1821-2794(Online)



Review article                                                                                         UDC: 616.441-085:546.23                                                                                                            doi:10.5633/amm.2015.0109




Milica Pešić1,2, Danijela Radojković1,2

Clinic of Endocrinology, Clinical Center Niš, Serbia1

University of Niš, Faculty of Medicine, Niš, Serbia2


                         Contact: Milica Pešić
                        Clinic of Endocrinology, Clinical Center Niš, Serbia
                        Bul. Zorana Đinđića 48, 18000 Niš
                        E mail: mimapesic@gmail.com

The understanding of the essential role of selenium (Se) in thyroid hormone synthesis, metabolism and action, as well as normal thyroid function, increased during the past decades. The thyroid gland is among the human tissues with the highest Se content per mas unit, similar to other endocrine organs and brain.

 Biological actions of Se are mediated, in most cases, through the expression of at least 30 selenoproteins coded by 25 selenoprotein genes in the human. Via the selenoproteins, selenium can influence the cell function through antioxidant activites, modifying redox status and thyroid hormone synthesis and metabolism. Selenoproteins iodothyronine deiodinases are present in most tissues and have a role to increase the production of bioactive tri-iodothyronine.

Futhermore, Se has been shown to be important in the regulation of immune function. Se deficiency is accompained by the loss of immune competence. The links between Se deficiency, altered immune function and inflamation have prompted studies in humans to examine if Se suplementation can modify auto-antibodies production in patients with chronic autoimmune thyroiditis. Until now, several randomised prospective clinical trials have been performed in patients with established chronic autoimmune thyrioditis. The clinical endpoint of each study was the decrease in TPO antibodies concentration after 3-12 months of treatment. Ussualy, the dosage of daily Se supplementation was 200g. Selenium suplemetation had no significant effect on the concentration of TSH or thyroid hormone concentrations. These studies indicate that Se treatment result in reduced inflammatory activity, but it does not cure chronc autoimmune process. Acta Medica Medianae 2015;54(1): 56-59.


Key words: thyroid gland, trace element, selenium